Contact Congress about S. 1302: Increasing Transparency in Generic Drug Applications Act

Generic drug companies would get clearer FDA feedback on whether their products match a brand-name drug. If key inactive ingredients differ, the FDA would have to say what differs and by how much.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Increasing Transparency in Generic Drug Applications Act is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest action on S. 1302: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Who this affects: This bill mainly affects generic drug companies because it gives them clearer FDA feedback while they prepare or file applications. It also affects brand-name drug companies because the FDA may share more information tied to their drug formulas. Patients, doctors, pharmacies, and insurers could be affected later if the bill changes how quickly generic drugs reach the market, but the bill does not promise that result.

Why this matters: Generic drugs can cost less, but companies must first prove they match the brand-name drug in required ways. This bill could make that process clearer for generic drug makers by forcing the FDA to explain ingredient-match problems. That could help companies fix applications sooner. At the same time, the bill raises questions about how much private brand-name drug information the FDA should share.

Key provisions in S. 1302

• The FDA must tell a generic drug company whether its product matches the brand-name drug in the needed way. This applies only when the bill's conditions are met.
• The bill applies when a generic drug must use the same inactive ingredients in the same strengths as the brand-name drug. It also applies when the FDA allows lab tests to prove the generic works like the brand drug under those same conditions.
• If the generic drug does not match, the FDA must say which ingredients are different. If the amount is different, the FDA must say how big the difference is.
• The bill says the FDA is legally allowed to share this information with the generic applicant. It also says the brand drug's detailed formula can still count as a trade secret or private business information.
• After a generic company files its application, the FDA usually cannot take back a finding that the drug matches. The FDA can do so only for listed safety reasons, effectiveness reasons, or to fix an error.

How Modern Action helps you take action on S. 1302

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 1302

What is S. 1302?

Generic drug companies would get clearer FDA feedback on whether their products match a brand-name drug. If key inactive ingredients differ, the FDA would have to say what differs and by how much.

How do I support or oppose S. 1302?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 1302?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain S. 1302 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.